Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 27, 2026.

Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease

Donald P Tashkin, Gary T Ferguson

Respiratory Research · 2013 · Review

doi:10.1186/1465-9921-14-49

Abstract

Chronic obstructive pulmonary disease (COPD) represents a significant cause of global morbidity and mortality, with a substantial economic impact. Recent changes in the Global initiative for chronic Obstructive Lung Disease (GOLD) guidance refined the classification of patients for treatment using a combination of spirometry, assessment of symptoms, and/or frequency of exacerbations. The aim of treatment remains to reduce existing symptoms while decreasing the risk of future adverse health events. Long-acting bronchodilators are the mainstay of therapy due to their proven efficacy. GOLD guidelines recommend combining long-acting bronchodilators with differing mechanisms of action if the control of COPD is insufficient with monotherapy, and recent years have seen growing interest in the additional benefits that combination of long-acting muscarinic antagonists (LAMAs), typified by tiotropium, with long-acting β(2)-agonists (LABAs), such as formoterol and salmeterol. Most studies have examined free combinations of currently available LAMAs and LABAs, broadly showing a benefit in terms of lung function and other patient-reported outcomes, although evidence is limited at present. Several once- or twice-daily fixed-dose LAMA/LABA combinations are under development, most involving newly developed monotherapy components. This review outlines the existing data for LAMA/LABA combinations in the treatment of COPD, summarizes the ongoing trials, and considers the evidence required to inform the role of LAMA/LABA combinations in treatment of this disease.

Shown for reading. Its publisher allows quoting it, not republishing it.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 27, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Currently the fourth leading cause of death globally, chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality, projected to become the world’s third leading cause of mortality by 2020. Characterized by progressive airflow limitation, COPD also has a major economic impact, contributing to US$53.7 billion in related direct costs in 2008 in the US.

As an area of interest for physicians, and a logical progression from monotherapy for those seeking to further improve outcomes in patients with respiratory disease, the subject of combined bronchodilation with bronchodilators of differing modes of action has been discussed in the literature previously. The aim of this review is to focus more specifically on the combination of long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs) for the treatment of COPD, summarizing data from recent peer-reviewed publications and published abstracts.

Evolving COPD guidelines

2011 saw a substantial revision of the Global initiative for chronic Obstructive Lung Disease (GOLD) guidelines for diagnosis, management, and prevention of COPD, which has recently been updated. Recommendations for treatment are no longer based primarily on categorization (“staging”) by spirometric assessment, but on categorization by existing symptoms (using validated modified Medical Research Council and COPD Assessment Test questionnaires) and risk (based on severity of airflow limitation and history of exacerbations). This approach acknowledges the importance of consideration of both short- and long-term outcomes when making treatment decisions (Figure 1).

Long-acting bronchodilators: the cornerstone of COPD maintenance therapy

Two key classes of bronchodilators have been developed in COPD: β2-agonists and muscarinic antagonists. Short-acting bronchodilators, such as ipratropium, albuterol, and metaproterenol, have formed the cornerstone of initial COPD therapy for the past two decades. Subsequently, long-acting bronchodilators were developed. The twice-daily LABAs salmeterol and formoterol first became available for maintenance therapy of COPD more than 15 years ago, while the once-daily LAMA tiotropium has been available for 10 years and is the most widely prescribed maintenance monotherapy bronchodilator in COPD. Inhaled bronchodilators, as monotherapy or in combination, remain the mainstay for patients in all categories (Table 1). Long-acting bronchodilators, such as tiotropium, formoterol, and salmeterol, are proven to provide long-term improvements in lung function, quality of life, and exacerbations in patients with COPD. Long-acting bronchodilators (e.g., tiotropium, salmeterol) also reduce lung hyperinflation and dyspnea, and increase exercise endurance, although a recent review suggested further data are required on the benefits of long-acting bronchodilators on exercise tolerance. There are a variety of long-acting bronchodilators available (Table 2). The once-daily LABA indacaterol, the once-daily LAMA glycopyrronium, and twice-daily LAMA aclidinium represent newer, recently licensed therapies, and there are also several once-daily LABAs and LAMAs in development, including olodaterol, vilanterol, and glycopyrrolate (Table 2).

Combination bronchodilation: rationale

Guidelines recommend combination therapy involving two long-acting bronchodilators with differing modes of action in patients whose COPD is not sufficiently controlled with monotherapy (Table 1). The mechanistic rationale for combination of a muscarinic antagonist and a β2-agonist has been reviewed in detail recently; as such, we will only briefly discuss it here. Airway smooth muscle relaxation (leading to bronchodilation) can be achieved via two main routes: inhibition of acetylcholine signaling via muscarinic M3 receptors on airway smooth muscle with a muscarinic antagonist, or stimulation of β2-adrenoceptors with a β2-agonist. Targeting these two mechanisms of bronchoconstriction, theoretically, has the potential to maximize the bronchodilator response without increasing the dose of either component, and helps to overcome the inter- and intra-patient variability in response to individual agents seen in COPD. The interaction between the two systems has yet to be fully elucidated; however, β2-agonists can amplify the bronchial smooth muscle relaxation directly induced by the muscarinic antagonist by decreasing the release of acetylcholine via modulation of cholinergic neurotransmission. Additionally, muscarinic antagonists have been demonstrated to augment β2-agonist-stimulated bronchodilation by reducing the bronchoconstrictor effects of acetylcholine in preclinical models.

The rationale for improved bronchodilation has been tested in preclinical models with a specific investigational LAMA/LABA combination, tiotropium plus olodaterol, demonstrating synergistic effects on bronchoprotection in vivo. Combination treatment in ovalbumin-induced bronchoconstriction in anesthetized guinea pigs has demonstrated improved bronchoprotection in a dose-dependent manner, with effective dose (ED) 50 values 10-fold lower than the ED50 of olodaterol alone (p < 0.05); similar results were reported versus tiotropium monotherapy in acetylcholine-induced bronchoconstriction in anesthetized dogs. Indacaterol synergistically potentiates the effects of glycopyrronium to inhibit metacholine-induced contraction of airway smooth muscle in vitro. However, specifically designed clinical studies are required to assess whether such synergistic effects can be observed with therapeutic doses in humans.

Short-acting muscarinic antagonist plus short-acting β2-agonist

The concept of adding a muscarinic antagonist to a β2-agonist is by no means new. A fixed-dose combination (FDC) of the short-acting agents ipratropium and albuterol (Combivent®) and of fenoterol and ipratropium (Berodual®) clearly provides benefits over monotherapy with either component. Additionally, dual bronchodilation with ipratropium and albuterol resulted in a consistently longer response and more patients achieved a pre-specified response level (12-15%) in forced expiratory volume in 1 second (FEV1) with the combination versus individual components (p < 0.05), with an equivalent or improved safety profile.

Free combinations of LAMA plus LABA

Relatively few studies have examined the combination of LAMAs and LABAs. Until recently, research focused on free combinations of existing therapies, and has demonstrated benefits on lung function and other outcomes (Table 3).

Following proof of concept in terms of a benefit on FEV1 and in patients with acute exacerbations, several randomized controlled trials have reported improved lung function for tiotropium plus formoterol versus tiotropium alone. Some trials have also identified significant improvements in symptom scores and reductions in rescue medication use. A recent meta-analysis confirmed the benefits of tiotropium plus formoterol on average FEV1, trough FEV1, and Transition Dyspnea Index (TDI) (Table 3), with initial reports also suggesting that the combination may provide statistically significant improvements in effort-induced dynamic hyperinflation and exercise tolerance.

Currently available data on tiotropium plus salmeterol are conflicting. Initial investigations indicated the benefits of tiotropium plus salmeterol versus either monotherapy alone, while suggesting co-administration of once-daily salmeterol plus tiotropium was inadvisable, due to the shorter duration of bronchodilation provided by salmeterol. The Canadian Optimal Therapy of COPD trial investigated the impact of tiotropium plus placebo, tiotropium plus salmeterol, or tiotropium plus salmeterol/fluticasone on clinical outcomes in 449 patients with moderate to severe COPD. Tiotropium plus salmeterol/fluticasone (but not tiotropium plus salmeterol) statistically improved lung function and quality of life, and, while no improvement in overall exacerbation rate was seen, reduced the number of hospitalizations for exacerbations compared to tiotropium plus placebo (Table 3). A more recent study, however, demonstrated significant improvements in FEV1 with salmeterol once or twice daily plus tiotropium, and the combination was also associated with clinically significant improvements in TDI (Table 3). These inconclusive data suggest that further research is necessary to determine any advantage of salmeterol plus tiotropium. Initial investigation of other free combinations has also been reported (Table 3); tiotropium plus indacaterol has been demonstrated to improve lung function and inspiratory capacity, as well as providing a further reduction in use of rescue medication. The LAMA GSK233705 twice daily plus salmeterol has also demonstrated significantly improved trough FEV1 from baseline compared to monotherapy. Overall, these data broadly confirm that combination therapy has the potential to improve outcomes versus monotherapy and justify further research in this area.

Fixed-dose combinations (FDCs)

FDCs of LAMAs and LABAs offer the potential of improved convenience and compliance over use of separate inhalers, and, during their development, the dose of each agent to be used in combination can be optimized.

A major challenge associated with development of an FDC is provision of improved bronchodilation over monotherapy components while balancing the associated adverse effects. Dose-finding studies are required to establish minimal effective doses for each agent in the combination, as it cannot be assumed that these doses are the same as would be used in monotherapy. Regulatory bodies also require investigation into any pharmacodynamic or pharmacokinetic interactions that may occur between the constituents, along with evidence of the safety profile for the combination.

A number of FDCs are in development, with substantial clinical programs (Table 4), and some Phase II/III results are available (Table 3). In all cases, there is evidence of improved lung function parameters with the combinations versus monotherapy components. Glycopyrrolate/glycopyrronium is being developed as part of two combinations: the former plus formoterol as a twice-daily combination (Pearl Therapeutics) and the latter plus indacaterol as a once-daily combination (Novartis). Glycopyrrolate plus formoterol has recently reported improvements in FEV1 area under the curve from 0–12 hours (AUC0-12) versus monotherapy with glycopyrrolate, formoterol, or tiotropium, and in inspiratory capacity versus tiotropium monotherapy (Table 3). Indacaterol is approved at doses of 150 and 300 μg in the EU, and 75 μg in the US. Early studies investigated high doses of indacaterol in combination with glycopyrronium, but the recent SHINE, ILLUMINATE, and ENLIGHTEN studies have examined the effects of indacaterol (110 μg) plus glycopyrronium (50 μg) (Table 3). The SHINE study reported significantly greater improvements in trough FEV1 after 26 weeks’ treatment with the combination compared to monotherapy with indacaterol (mean difference 70 mL), glycopyrronium (90 mL), or tiotropium (80 mL). This study also demonstrated improvements in dyspnea (versus placebo and tiotropium), St George’s Respiratory Questionnaire (versus placebo), and reduced use of rescue medication (versus placebo and all monotherapies). The ILLUMINATE study has provided interesting information on the relative effects on lung function of a LABA/LAMA combination versus LABA/inhaled corticosteroids (ICS): significant, sustained, and clinically meaningful improvements in trough FEV1, peak FEV1, and FEV1 AUC0-12 with indacaterol plus glycopyrronium versus the LABA/ICS salmeterol/fluticasone (p < 0.001 for all comparisons). Mean treatment difference for indacaterol plus glycopyrronium versus salmeterol/fluticasone ranged from 103 mL (trough FEV1) to 155 mL (peak FEV1). Additionally, the longer-term ENLIGHTEN study reported significant improvements in lung function with the combination versus placebo sustained for 52 weeks, with no evidence of tachyphylaxis.

Clinical Phase II trials have investigated the optimal dosing for olodaterol added to a fixed dose of tiotropium and for tiotropium added to a fixed dose of olodaterol. Significant improvements in peak FEV1 were demonstrated with tiotropium/olodaterol 5/2 μg (p = 0.008), 5/5 μg (p = 0.012), and 5/10 μg (p < 0.0001) versus tiotropium monotherapy. Significant improvements were also seen in trough FEV1 with tiotropium/olodaterol 5/10 μg versus tiotropium monotherapy (p = 0.034), and with all doses of the combination tested versus olodaterol monotherapy, with evidence of dose ordering (Table 3).

There is little information available from studies of aclidinium plus formoterol; only initial results of preclinical cardiac safety in beagle dogs have been reported.

Of the LAMA/LABA FDCs currently under investigation, tiotropium plus olodaterol, umeclidinium plus vilanterol, aclidinium plus formoterol, and glycopyrronium plus indacaterol have the largest Phase III programs, focusing on efficacy, safety, exacerbations, exercise, and dyspnea (Table 4). The development program for umeclidinium plus vilanterol involves four large pivotal trials, one large safety study, and two studies assessing exercise endurance, with two ongoing trials investigating lung function and efficacy. Phase III studies of glycopyrronium plus indacaterol will compare the combination with a range of comparators, including fluticasone/salmeterol combination and tiotropium, across a variety of end points (FEV1, exacerbations, TDI, and safety). The tiotropium plus olodaterol development program includes two main registration trials, three examining exercise and functional capacity, one examining long-term safety, and a comprehensive lung function trial.

Several of the LAMA/LABA FDCs in development will be delivered once daily (such as umeclidinium plus vilanterol and tiotropium plus olodaterol) while others will have twice-daily dosing (e.g., aclidinium plus formoterol). This diversity has the potential to increase the personalization of medication to individual needs; for instance, twice-daily combinations could be considered where patients suffer from night-time symptoms, while once-daily combinations may be prescribed to improve adherence.

Delivery devices

Inhalation devices are intrinsically linked to the medication they deliver. As such, careful consideration of the most appropriate delivery device is crucial to optimal COPD therapy, along with adequate training and observation of patient technique.

The new devices currently in development for delivery of combination inhaled LAMA/LABAs for COPD fall into three main classes: pressurized metered dose inhalers (pMDIs), dry powder inhalers (DPIs), and a propellant-free Soft Mist™ Inhaler (SMI), each with its own advantages and disadvantages (Table 5). Poor inhaler technique is often a main cause of sub-optimal COPD management; determining a suitable delivery device that each individual patient will be able to use can help to ensure adequate disease management. For instance, a spacer or holding chamber can be used to improve drug delivery via pMDIs in patients with poor coordination between actuation and inhalation. DPIs were designed to ease operation compared to pMDIs. However, it remains important to provide patient training on the specific DPI, as confusion can arise regarding the differing loading techniques for individual devices (e.g., self-contained reservoirs or blister packs versus capsule insertion). Additionally, a higher inspiratory flow is required to operate this type of inhaler, meaning that it may not be appropriate for patients with very severe COPD. The increased aerosol production time provided by an SMI (1.5 seconds compared to <0.5 seconds for most other inhalers) may be an advantage for patients with low inspiratory capacity or poor timing of inhalation to actuation, although teaching and observing the patient’s technique remains important.

Non-adherence is a well-documented issue in COPD and is associated with detrimental effects on patient outcomes. Irrespective of the device type, a single device with once-daily dosing may provide a significant advantage, potentially improving adherence and, therefore, patient outcomes. Adherence is inversely related to the number of medications patients take and both treatment persistence and adherence in patients with COPD have been demonstrated to be lower in multiple long-acting inhaler users, compared to single long-acting inhaler users. Additionally, a recent large retrospective study reported that adherence was significantly higher in those who initiated treatment with once-daily dosing versus more frequent dosing. On the other hand, apart from the possible advantage of once- over twice-daily dosing on adherence, a twice-daily preparation has the potential advantage of greater improvement in night-time airflow and symptoms, an issue that has recently been reappraised.

Consideration of potential adverse effects of LAMA/LABA combinations

The safety profiles of both LAMAs and LABAs are well understood. However, when combining two entities, it is important to understand both the similarities and differences in adverse events. Given that both muscarinic antagonists and β2-agonists can have a detrimental effect on the cardiovascular system, these adverse events need to be monitored carefully in development programs for combination products. Initial results suggest that the cardiovascular safety profile of glycopyrronium plus indacaterol is similar to placebo, with no clinically significant differences observed versus placebo, and, to date, no safety concerns have been identified with tiotropium plus olodaterol. Free combinations of LAMA/LABA also seem well tolerated. No differences in blood pressure and pulse rate were observed with tiotropium plus salmeterol versus single-agent therapies and the meta-analysis of tiotropium plus formoterol data reported no differences in cumulative incidence of adverse events for the combination (33.2%) versus tiotropium alone (36.0%), stating that drug-related severe adverse events and cardiac effects were relatively rare.

Triple therapy

Triple therapy with LAMA plus LABA/ICS has also been investigated, demonstrating benefits over monotherapy on lung function. Additionally, a pilot study of patients with advanced COPD reported that triple therapy combined with pulmonary rehabilitation provided a benefit in terms of lung function. Some reports also suggest that triple therapy can provide additional benefits, such as reduction in exacerbation rate and mortality, although a recent systematic review concluded that further, longer-term studies are required to determine the benefits of tiotropium plus LABA and ICS, or the additional benefit of ICS on top of LAMA/LABA combinations.

Dual muscarinic antagonist-β2-agonists (MABAs)

Another interesting concept is that of single molecules with muscarinic antagonist-β2-agonist (MABA) activity. While the prospect of combining muscarinic antagonism and β2-agonism into one entity is highly attractive, this is a new and challenging area of research. The optimal MABA should be designed to achieve balanced, high potencies at both muscarinic and β2 receptors, for consistency. The furthest developed MABA is GSK961081, which has demonstrated effective bronchoprotection in vivo as proof of concept (NCT00478738) and is currently in Phase IIb studies. MABAs provide a fixed ratio of muscarinic antagonist and β2-agonist activity at a cellular level, have a single pharmacokinetic profile, and deliver a fixed ratio of muscarinic antagonist and β2-agonist to the whole lung, simplifying both combination delivery device and clinical development programs. These properties suggest that MABAs have the potential to act as a useful platform for triple therapy with an anti-inflammatory agent.

Novel bronchodilators

A number of new bronchodilators with novel modes of action are currently in early stages of development, including K+ channel openers, Rho kinase inhibitors, and analogs of vasoactive intestinal peptide; these have been reviewed more extensively elsewhere. Given the substantial evidence supporting a role of Rho kinase in bronchoconstriction, Rho kinase inhibitors such as Y-27632, Y-30141, Y-30694, and fasudil may currently hold the most promise, demonstrating smooth muscle relaxant properties in vitro. Once further evidence of efficacy and safety is available, these newer classes might be used in combination with more conventional bronchodilators, leading to additional therapeutic options and increased potential for individualized medication.

Conclusions

In summary, there is considerable evidence and guidance to support use of the combination of a LAMA and a LABA in COPD, a number of free LAMA and LABA combinations have been studied, and several LABA/LAMA FDCs are under development.

Although there is a clear rationale for the use of LAMA and LABA combinations, a recent treatment regimen analysis for patients with COPD (based on prescription and medical claims) suggests that currently this free combination is utilized much less frequently than LAMA monotherapy (tiotropium), LABA/ICS combinations, and the triple combination of LAMA plus LABA/ICS in clinical practice (Table 6). These data show that regardless of the presence or absence of comorbid asthma, LABA/ICS is the most widely used of these regimens, followed by tiotropium monotherapy. Interestingly, triple therapy is already a substantially used therapeutic option (usage approximately 60% of that of tiotropium monotherapy). LABA/ICS is more frequently used in patients with comorbid asthma and COPD. While this practice is to be expected, it is likely that the perceived overlap between asthma and COPD is exaggerated due to the common misconception that a significant bronchodilator response in patients with COPD implies the coexistence of an asthmatic component.

The very limited clinical use of LAMA/LABA combination therapy indicated by these data is perhaps surprising, given the current evidence base and GOLD guidance. However, the evidence from ongoing programs will be much more substantial and the future availability of LAMA/LABA FDCs should make this therapeutic option more convenient than separate administration by two inhalers (typically with different dosing schedules), currently the only option.

The rising number of both single-agent and combination therapies for COPD increases the number of treatment options, and, hence, makes treatment choice more complex. Further studies should be designed to provide substantial evidence for future guideline recommendations. In particular, investigation into the optimal sequencing of monotherapies and combination bronchodilators would be of use to determine where LAMA/LABA FDC therapy may be positioned in the treatment algorithm for COPD. Furthermore, examination of the benefits of using dual bronchodilation as initial maintenance therapy would be of interest, along with which groups of patients may benefit from this approach.

There is a growing appreciation of the benefits of bronchodilation beyond lung function, such as exacerbations, patient-reported outcomes, exercise tolerance and exercise capacity, and daily activities. Trials of LABA/LAMA FDCs should assess this wider range of outcomes in order to more fully understand the broader benefits of increased bronchodilation on a patient’s life as a whole.

Abbreviations

AUC0-12: Area under the curve from 0–12 hours; COPD: Chronic obstructive pulmonary disease; DPI: Dry powder inhaler; ED: Effective dose; FDC: Fixed-dose combination; FEV1: Forced expiratory volume in 1 second; GOLD: Global initiative for chronic Obstructive Lung Disease; ICS: Inhaled corticosteroid; LABA: Long-acting β2-agonist; LAMA: Long-acting muscarinic antagonist; MABA: Muscarinic antagonist-β2-agonist; pMDI: Pressurized metered dose inhaler; SMI: Soft Mist™ Inhaler; TDI: Transition Dyspnea Index.

Competing interests

DPT has received grant support from Boehringer Ingelheim, Pearl Therapeutics, Novartis, Forest, and GlaxoSmithKline, speaking fees from Boehringer Ingelheim, Novartis, and Forest, and undertaken consultancy for Pearl Therapeutics, Novartis, and Theravance.

GTF has received grant support from Boehringer Ingelheim, GlaxoSmithKline, Pearl Therapeutics, Novartis, Forest, and Pfizer, speaking fees from Boehringer Ingelheim, GlaxoSmithKline, Astra Zeneca, Novartis, and Forest, and has acted as an advisor to Boehringer Ingelheim, GlaxoSmithKline, Astra Zeneca, Pearl Therapeutics, Forest, and Novartis.

Authors’ contributions

DPT and GTF were responsible for the concept and design of the paper, preparation and revision of the draft, and take full responsibility for the final version of this manuscript.

References 112

  1. 1.

    World Health OrganizationWorld health statistics 2008http://www.who.int/whosis/whostat/2008/en/index.html

    Not in our library

  2. 2.

    Chapman KR Mannino DM Soriano JB Vermeire PA Buist AS Thun MJ Connell C Jemal A Lee TA Miravitlles M Aldington S Beasley R Epidemiology and costs of chronic obstructive pulmonary diseaseEur Respir J2006 27188207

    Not in our library10.1183/09031936.06.00024505

  3. 3.

    National Institutes of Health, National Heart, Lung, and Blood InstituteMorbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseaseshttp://www.nhlbi.nih.gov/resources/docs/2012_ChartBook.pdf

    Not in our library

  4. 4.

    Cazzola M Matera MG Emerging inhaled bronchodilators: an updateEur Respir J2009 34757769

    Not in our library10.1183/09031936.00013109

  5. 5.

    Cazzola M Calzetta L Matera MG β2-adrenoceptor agonists: current and future directionBr J Pharmacol2011 163417

    Not in our library10.1111/j.1476-5381.2011.01216.x

  6. 6.

    Matera MG Page CP Cazzola M Novel bronchodilators for the treatment of chronic obstructive pulmonary diseaseTrends Pharmacol Sci2011 32495506

    Not in our library10.1016/j.tips.2011.04.003

  7. 7.

    Cazzola M Page CP Calzetta L Matera MG Pharmacology and therapeutics of bronchodilatorsPharmacol Rev2012 64450504

    Not in our library10.1124/pr.111.004580

  8. 8.

    Cazzola M Rogliani P Segreti A Matera MG An update on bronchodilators in Phase I and II clinical trialsExpert Opin Investig Drugs2012 2114891501

    Not in our library10.1517/13543784.2012.710602

  9. 9.

    Global initiative for chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2013http://www.goldcopd.org/guidelines-global-strategy-for-diagnisis-management.pdf

    Not in our library

  10. 10.

    US Food and Drug AdministrationFDA approved drug products. Ipratropiumhttp://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm]

    Not in our library

  11. 11.

    Yohannes AM Willgoss TG Vestbo J Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomesRespir Care2011 56477487

    Not in our library10.4187/respcare.00852

  12. 12.

    Tashkin DP Celli B Senn S Burkhart D Kesten S Menjoge S Decramer M for the UPLIFT Study InvestigatorsA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008 35915431554

    Not in our library10.1056/nejmoa0805800

  13. 13.

    Dahl R Greefhorst LAPM Nowak D Nonikov V Byrne AM Thomson MH Till D Della Cioppa G on behalf of the Formoterol in Chronic Obstructive Pulmonary Disease I (FICOPD I) Study GroupInhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2001 164778784

    Not in our library10.1164/ajrccm.164.5.2007006

  14. 14.

    Cazzola M Santangelo G Piccolo A Salzillo A Matera MG D'Amato G Rossi F Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary diseasePulm Pharmacol1994 7103107

    Not in our library10.1006/pulp.1994.1012

  15. 15.

    O'Donnell DE Sciurba F Celli B Mahler DA Webb KA Kalberg CJ Knobil K Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPDChest2006 130647656

    Not in our library10.1378/chest.130.3.647

  16. 16.

    O'Donnell DE Flüge T Gerken F Hamilton A Webb K Aguilaniu B Make B Magnussen H Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J2004 23832840

    Not in our library10.1183/09031936.04.00116004

  17. 17.

    Aguilaniu B Impact of bronchodilator therapy on exercise tolerance in COPDInt J Chron Obstruct Pulmon Dis2010 55771

    Not in our library10.2147/copd.s7404

  18. 18.

    Casaburi R Briggs DD Jr Donohue JF Serby CW Menjoge SS Witek TJ Jr for the US Tiotropium Study GroupThe spirometric efficacy of once-daily dosing with tiotropium in stable COPD. A 13-week multicenter trialChest2000 11812941302

    Not in our library10.1378/chest.118.5.1294

  19. 19.

    Verkindre C Fukuchi Y Flémale A Takeda A Overend T Prasad N Dolker M Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patientsRespir Med2010 10414821489

    Not in our library10.1016/j.rmed.2010.04.006

  20. 20.

    Novartis Europharm LimitedSPC. Onbrez Breezhaler 150 and 300 microgram inhalation powder, hard capsuleshttp://www.medicines.org.uk/EMC/medicine/23260/SPC/Onbrez+Breezhaler+150+and+300+microgram+inhalation+powder%2c+hard+capsules/

    Not in our library

  21. 21.

    Novartis Pharmaceutical CorporationARCAPTA NEOHALER. Full prescribing informationhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022383s0002mg.pdf

    Not in our library

  22. 22.

    Moen MD Indacaterol. In chronic obstructive pulmonary diseaseDrugs2010 7022692280

    Not in our library10.2165/11203960-000000000-00000

  23. 23.

    Kerwin EM Meli J Peckitt C Lassen C Kramer B Filcek S Efficacy and safety of indacaterol 75 g [sic] once daily in patients with moderate-to-severe COPD [abstract]Am J Respir Crit Care Med2011 183A1595

    Not in our library10.1164/rccm.201011-1783oc

  24. 24.

    van Noord JA Korducki L Hamilton A Koker P Four weeks once daily treatment with BI 1744 CL, a novel long-acting β2-agonist, is effective in COPD patients [abstract A6183]Am J Respir Crit Care Med2009 179A6183

    Not in our library

  25. 25.

    Hanania NA Feldman G Zachgo W Shim JJ Crim C Sanford L Lettis S Barnhart F Haumann B Dose-related efficacy of vilanterol trifenatate (VI) in COPD [abstract P1227]Eur Respir J2010 36Suppl 54217s

    Not in our library

  26. 26.

    Tashkin DP Fabbri LM Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agentsRespir Res2010 11149

    Not in our library10.1186/1465-9921-11-149

  27. 27.

    Vestbo J Vogelmeier C Creemers J Falques M Ribera A Garcia Gil E Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPDCOPD2010 7331336

    Not in our library10.3109/15412555.2010.510158

  28. 28.

    Gavaldà A Miralpeix M Ramos I Otal R Carreño C Viñals M Doménech T Carcasona C Reyes B Vilella D Gras J Cortijo J Morcillo E Llenas J Ryder H Beleta J Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profileJ Pharmacol Exp Ther2009 331740751

    Not in our library10.1124/jpet.109.151639

  29. 29.

    Kerwin E D'Urzo A Gelb A Lakkis H Garcia Gil E Caracta C Twice-daily aclidinium bromide in COPD patients: efficacy and safety results from ACCORD COPD I [abstract P1235]Eur Respir J2010 36Suppl 54219s

    Not in our library

  30. 30.
    Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial · 2011
    No notice
  31. 31.

    Orevillo C St Rose E Strom S Fischer T Golden M Thomas M Reisner C Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD [abstract P3975]Eur Respir J2011 38Suppl 55724s

    Not in our library

  32. 32.

    Bateman E Feldman G Kilbride S Brooks J Mehta R Harris S Maden C Crater G Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPDClin Respir J2012 6248257

    Not in our library10.1111/j.1752-699x.2011.00278.x

  33. 33.

    Donohue JF Siler T Kerwin EM Williams J Kianifard F McBryan D Efficacy and safety of indacaterol 75 μg once daily in patients with moderate-to-severe COPD: pooled analysis of two phase III trials [abstract A2258]Am J Respir Crit Care Med2012 185A2258

    Not in our library

  34. 34.

    Kerwin EM Hebert J Pedinoff A Gallagher N Martin C Banerji D Lu Y Overend T NVA237 once daily provides rapid and sustained bronchodilation in COPD patients, with efficacy similar to tiotropium: the GLOW2 trial [abstract]Am J Respir Crit Care Med2012 185A2920

    Not in our library

  35. 35.

    Cazzola M Tashkin DP Combination of formoterol and tiotropium in the treatment of COPD: effects on lung functionCOPD2009 6404415

    Not in our library10.1080/15412550903156333

  36. 36.

    Cazzola M Molimard M The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPDPulm Pharmacol Ther2010 23257267

    Not in our library10.1016/j.pupt.2010.03.003

  37. 37.

    Bouyssou T Schnapp A Casarosa P Pieper MP Addition of the new once-daily LABA BI 1744 to tiotropium results in superior bronchoprotection in pre-clinical models [abstract A4445]Am J Respir Crit Care Med2010 181A4445

    Not in our library

  38. 38.

    Bouyssou T Casarosa P Pieper M Schnapp A Gantner F Synergistic bronchoprotective activity of the long-acting beta 2-agonist olodaterol with tiotropium (long-acting M3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumin-induced bronchoconstriction in anaesthetized guinea pigs [abstract 3451]Eur Respir J2011 38Suppl 55613s

    Not in our library

  39. 39.

    Kume H Imbe S Iwanaga T Tohda Y Synergistic effects between glycopyrronium bromide and indacaterol on a muscarinic agonist-induced contraction in airway smooth muscle [abstract 4835]Presented at the European Respiratory Society Annual Congress, Vienna, Austria, September 1–52012

    Not in our library

  40. 40.

    COMBIVENT Inhalation Solution Study GroupRoutine nebulized ipratropium and albuterol together are better than either alone in COPDChest1997 11215141521

    Not in our library10.1378/chest.112.6.1514

  41. 41.

    COMBIVENT Inhalation Aerosol Study GroupIn chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trialChest1994 10514111419

    Not in our library10.1378/chest.105.5.1411

  42. 42.

    Guleria R Behera D Jindal SK Comparison of bronchodilatation produced by an anticholinergic (ipratropium bromide), a beta-2 adrenergic (fenoterol) and their combination in patients with chronic obstructive airway disease. An open trialJ Assoc Physicians India1991 39680682

    Not in our library

  43. 43.

    ZuWallack R De Salvo MC Kaelin T Bateman ED Park CS Abrahams R Fakih F Sachs P Pudi K Zhao Y Wood CC on behalf of the Combivent Respimat® inhaler Study GroupEfficacy and safety of ipratropium bromide/albuterol delivered via Respimat® inhaler versus MDIRespir Med2010 10411791188

    Not in our library10.1016/j.rmed.2010.01.017

  44. 44.

    Dorinsky PM Reisner C Ferguson GT Menjoge SS Serby CW Witek TJ Jr The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPDChest1999 115966971

    Not in our library10.1378/chest.115.4.966

  45. 45.

    Campbell S For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol baseArch Intern Med1999 159156160

    Not in our library10.1001/archinte.159.2.156

  46. 46.

    van der Molen T Cazzola M Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomesPrim Care Respir J2012 21101108

    Not in our library10.4104/pcrj.2011.00102

  47. 47.

    van Noord JA Aumann JL Janssens E Verhaert J Smeets JJ Mueller A Cornelissen PJG Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPDChest2006 129509517

    Not in our library10.1378/chest.129.3.509

  48. 48.

    Aaron SD Vandemheen KL Fergusson D Maltais F Bourbeau J Goldstein R Balter M O'Donnell D McIvor A Sharma S Bishop G Anthony J Cowie R Field S Hirsch A Hernandez P Rivington R Road J Hoffstein V Hodder R Marciniuk D McCormack D Fox G Cox G Prins HB Ford G Bleskie D Doucette S Mayers I Chapman K Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trialAnn Intern Med2007 146545555

    Not in our library10.7326/0003-4819-146-8-200704170-00152

  49. 49.

    van Noord JA Aumann J-L Janssens E Smeets JJ Verhaert J Disse B Mueller A Cornelissen PJG Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEur Respir J2005 26214222

    Not in our library10.1183/09031936.05.00140404

  50. 50.

    Mahler DA D'Urzo A Peckitt C Lassen C Kramer B Filcek S Combining once-daily bronchodilators in COPD: indacaterol plus tiotropium versus tiotropium alone [abstract]Am J Respir Crit Care Med2011 183A1591

    Not in our library

  51. 51.

    Maltais F Beck E Webster D Maleki-Yazdi MR Seibt J-V Arnoux A Hamilton A Four weeks once daily treatment with tiotropium + olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients [abstract 5557]Eur Respir J2010 36Suppl 541014s

    Not in our library

  52. 52.

    Reisner C St Rose E Strom S Fischer T Golden M Thomas M Orevillo C Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD [abstract P879]Eur Respir J2011 38Suppl 55150s

    Not in our library

  53. 53.

    Reisner C Fogarty C Spangenthal S Dunn L Kerwin EM Quinn D Seale JP Thomas M St Rose E Orevillo CJ Novel combination of glycopyrrolate and formoterol MDI (GFF-MDI) provides superior bronchodilation compared to its components administered alone, tiotropium DPI, and formoterol DPI in a randomized, double-blind, placebo-controlled Phase 2b study in patients with COPD [abstract]Am J Respir Crit Care Med2011 183A6453

    Not in our library

  54. 54.

    Vogelmeier C Kardos P Harari S Gans SJM Stenglein S Thirlwell J Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month studyRespir Med2008 10215111520

    Not in our library10.1016/j.rmed.2008.07.020

  55. 55.

    Tashkin DP Pearle J Iezzoni D Varghese ST Formoterol and tiotropium compared with tiotropium alone for treatment of COPDCOPD2009 61725

    Not in our library10.1080/15412550902724073

  56. 56.

    Tashkin DP Littner M Andrews CP Tomlinson L Rinehart M Denis-Mize K Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trialRespir Med2008 102479487

    Not in our library10.1016/j.rmed.2007.12.019

  57. 57.

    Van de Maele B Fabbri LM Martin C Horton R Dolker M Overend T Cardiovascular safety of QVA149, a combination of indacaterol and NVA237, in COPD patientsCOPD2010 7418427

    Not in our library10.3109/15412555.2010.528812

  58. 58.

    van Noord JA Buhl R LaForce C Martin C Jones F Dolker M Overend T QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary diseaseThorax2010 6510861091

    Not in our library10.1136/thx.2010.139113

  59. 59.

    van Noord JA Aumann J-L Janssens E Smeets JJ Zaagsma J Mueller A Cornelissen PJG Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptomsRespir Med2010 1049951004

    Not in our library10.1016/j.rmed.2010.02.017

  60. 60.

    Tashkin DP Donohue JF Mahler DA Huang H Goodwin E Schaefer K Hanrahan JP Andrews WT Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPDRespir Med2009 103516524

    Not in our library10.1016/j.rmed.2008.12.014

  61. 61.

    Beier J van Noord J Deans A Brooks J Maden C Baggen S Mehta R Cahn A Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patientsInt J Chron Obstruct Pulmon Dis2012 7153164

    Not in our library10.2147/copd.s26100

  62. 62.

    Reisner C Fernandez C Orevillo C St Rose E Kollar C Pearl Therapeutics' combination LAMA/LABA MDI (GFF MDI, PT003) provides comparable metabolic and ECG safety to Spiriva® HandiHaler® and placebo in patients with COPD [abstract]Am J Respir Crit Care Med2012 185A2925

    Not in our library

  63. 63.

    Feldman G Walker RR Brooks J Mehta R Crater G Safety and tolerability of the GSK573719/vilanterol combination in patients with COPD [abstract A2938]Am J Respir Crit Care Med2012 185A2938

    Not in our library

  64. 64.

    Aalbers R Maleki-Yazdi MR Hamilton A Waitere-Wijker S Pivovarova A Schmidt O Bjermer L Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPDPresented at the European Respiratory Society Annual Congress, Vienna, Austria, September 1–5. [abstract 2882]2012

    Not in our library

  65. 65.

    Hanania NA Boota A Kerwin E Tomlinson L Denis-Mize K Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: results from a 6-week, randomized, placebo-controlled, clinical trialDrugs2009 6912051216

    Not in our library10.2165/00003495-200969090-00005

  66. 66.

    Terzano C Petroianni A Conti V Ceccarelli D Graziani E Sanduzzi A D'Avelli S Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPDRespir Med2008 10217011707

    Not in our library10.1016/j.rmed.2008.07.012

  67. 67.

    Dahl R Chapman K Rudolf M Mehta R Kho P Alagappan V Berhane I Chen H Banerji D QVA149 administered once daily provides significant improvements in lung function over 1 year in patients with COPD: the ENLIGHTEN study [abstract 2896]Presented at the European Respiratory Society Annual Congress, Vienna, Austria, September 1–52012

    Not in our library

  68. 68.

    Bateman E Ferguson GT Barnes N Gallagher N Green Y Horton R Henley M Banerji D Benefits of dual bronchodilation with QVA149 once daily versus placebo, indacaterol, NVA237 and tiotropium in patients with COPD: the SHINE study [abstract 2810]Presented at the European Respiratory Society Annual Congress, Vienna, Austria, September 1–52012

    Not in our library

  69. 69.

    Vogelmeier CF Bateman ED Pallante J Alagappan VKT D'Andrea P Chen H Banerji D Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Resp Med2013 15160

    Not in our library10.1016/s2213-2600(12)70052-8

  70. 70.

    Cazzola M Di Marco F Santus P Boveri B Verga M Matera MG Centanni S The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPDPulm Pharmacol Ther2004 173539

    Not in our library10.1016/j.pupt.2003.09.001

  71. 71.

    Cazzola M Noschese P Salzillo A De Giglio C D'Amato G Matera MG Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patientsRespir Med2005 99524528

    Not in our library10.1016/j.rmed.2004.10.004

  72. 72.

    Di Marco F Verga M Santus P Morelli N Cazzola M Centanni S Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot studyRespir Med2006 10019251932

    Not in our library10.1016/j.rmed.2006.03.007

  73. 73.

    Rabe KF Timmer W Sagkriotis A Viel K Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPDChest2008 134255262

    Not in our library10.1378/chest.07-2138

  74. 74.

    Wang J Jin D Zuo P Wang T Xu Y Xiong W Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysisRespirology2011 16350358

    Not in our library10.1111/j.1440-1843.2010.01912.x

  75. 75.

    Berton DC Reis M Siqueira AC Barroco AC Takara LS Bravo DM Andreoni S Neder JA Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPDRespir Med2010 10412881296

    Not in our library10.1016/j.rmed.2010.05.017

  76. 76.

    Cazzola M Centanni S Santus P Verga M Mondoni M Di Marco F Matera MG The functional impact of adding salmeterol and tiotropium in patients with stable COPDRespir Med2004 9812141221

    Not in our library10.1016/j.rmed.2004.05.003

  77. 77.

    European Medicines AgencyGuideline on the non-clinical development of fixed combinations of medicinal productshttp://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500003976.pdf

    Not in our library

  78. 78.

    US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research (CDER)Guidance for industry. Chronic obstructive pulmonary disease: developing drugs for treatment. Draft guidancehttp://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071575.pdf

    Not in our library

  79. 79.

    Chowdhury BA Seymour SM Michele TM Durmowicz AG Liu D Rosebraugh CJ The risks and benefits of indacaterol — the FDA's reviewN Engl J Med2011 36522472249

    Not in our library10.1056/nejmp1109621

  80. 80.

    Gavalda A Vinyals M Aubets J Gras J Effect of formoterol alone and in combination with aclidinium on electrocardiograms in dogs [abstract 2116]Presented at the European Respiratory Society Annual Congress, Vienna, Austria, September 1–52012

    Not in our library

  81. 81.

    Agusti A Hedner J Marin JM Barbé F Cazzola M Rennard S Night-time symptoms: a forgotten dimension of COPDEur Respir Rev2011 20183194

    Not in our library10.1183/09059180.00004311

  82. 82.

    Toy EL Beaulieu NU McHale JM Welland TR Plauschinat CA Swensen A Duh MS Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costsRespir Med2011 105435441

    Not in our library10.1016/j.rmed.2010.09.006

  83. 83.

    Yawn BP Colice GL Hodder R Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the primary care settingInt J Chron Obstruct Pulmon Dis2012 7495502

    Not in our library10.2147/copd.s32674

  84. 84.

    Brocklebank D Ram F Wright J Barry P Cates C Davies L Douglas G Muers M Smith D White J Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literatureHealth Technol Assess2001 51149

    Not in our library10.3310/hta5260

  85. 85.

    Dalby R Spallek M Voshaar T A review of the development of Respimat® Soft Mist™ InhalerInt J Pharm2004 28319

    Not in our library10.1016/j.ijpharm.2004.06.018

  86. 86.

    Lechuga-Ballesteros D Noga B Vehring R Cummings RH Dwivedi SK Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthmaFuture Med Chem2011 317031718

    Not in our library10.4155/fmc.11.133

  87. 87.

    Pavkov R Mueller S Fiebich K Singh D Stowasser F Pignatelli G Walter B Ziegler D Dalvi M Dederichs J Rietveld I Characteristics of a capsule based dry powder inhaler for the delivery of indacaterolCurr Med Res Opin2010 2625272533

    Not in our library10.1185/03007995.2010.518916

  88. 88.

    Chrystyn H Niederlaender C The Genuair® inhaler: a novel, multidose dry powder inhalerInt J Clin Pract2012 66309317

    Not in our library10.1111/j.1742-1241.2011.02832.x

  89. 89.

    Larsen JS Hahn M Ekholm B Wick KA Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patientsJ Asthma1994 31193199

    Not in our library10.3109/02770909409044826

  90. 90.

    Goodman DE Israel E Rosenberg M Johnston R Weiss ST Drazen JM The influence of age, diagnosis, and gender on proper use of metered-dose inhalersAm J Respir Crit Care Med1994 15012561261

    Not in our library10.1164/ajrccm.150.5.7952549

  91. 91.

    Brand P Hederer B Austen G Dewberry H Meyer T Higher lung deposition with Respimat® Soft Mist™ Inhaler than HFA-MDI in COPD patients with poor techniqueInt J Chron Obstruct Pulmon Dis2008 3763770

    Not in our library

  92. 92.

    Lavorini F Magnan A Dubus JC Voshaar T Corbetta L Broeders M Dekhuijzen R Sanchis J Viejo JL Barnes P Corrigan C Levy M Crompton GK Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPDRespir Med2008 102593604

    Not in our library10.1016/j.rmed.2007.11.003

  93. 93.

    Hochrainer D Hölz H Kreher C Scaffidi L Spallek M Wachtel H Comparison of the aerosol velocity and spray duration of Respimat® Soft Mist™ Inhaler and pressurized metered dose inhalersJ Aerosol Med2005 18273282

    Not in our library10.1089/jam.2005.18.273

  94. 94.

    Geller DE Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhalerRespir Care2005 5013131321

    Not in our library

  95. 95.

    Wieshammer S Dreyhaupt J Dry powder inhalers: which factors determine the frequency of handling errors?Respiration2008 751825

    Not in our library10.1159/000109374

  96. 96.

    Lareau SC Yawn BP Improving adherence with inhaler therapy in COPDInt J Chron Obstruct Pulmon Dis2010 5401406

    Not in our library10.2147/copd.s14715

  97. 97.

    Melani AS Bonavia M Cilenti V Cinti C Lodi M Martucci P Serra M Scichilone N Sestini P Aliani M Neri M on behalf of the Gruppo Educazionale Associazione Italiana Pnemologi Ospedalieri (AIPO)Inhaler mishandling remains common in real life and is associated with reduced disease controlRespir Med2011 105930938

    Not in our library10.1016/j.rmed.2011.01.005

  98. 98.

    Yu AP Guérin A Ponce de Leon D Ramakrishnan K Wu EQ Mocarski M Blum S Setyawan J Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalersJ Med Econ2011 14486496

    Not in our library10.3111/13696998.2011.594123

  99. 99.

    Kesten S Jara M Wentworth C Lanes S Pooled clinical trial analysis of tiotropium safetyChest2006 13016951703

    Not in our library10.1378/chest.130.6.1695

  100. 100.

    Jung KS Park HY Park SY Kim SK Kim Y-K Shim J-J Moon HS Lee KH Yoo J-H Lee SD Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled studyRespir Med2012 106382389

    Not in our library10.1016/j.rmed.2011.09.004

  101. 101.

    Chatterjee A Shah M D'Souza AO Bechtel B Crater G Dalal AA Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary diseaseRespir Res2012 1315

    Not in our library10.1186/1465-9921-13-15

  102. 102.

    Welte T Miravitlles M Hernandez P Eriksson G Peterson S Polanowski T Kessler R Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2009 180741750

    Not in our library10.1164/rccm.200904-0492oc

  103. 103.

    Pasqua F Biscione G Crigna G Auciello L Cazzola M Combining triple therapy and pulmonary rehabilitation in patients with advanced COPD: a pilot studyRespir Med2010 104412417

    Not in our library10.1016/j.rmed.2009.10.005

  104. 104.

    Short PM Williamson PA Elder DHJ Lipworth SIW Schembri S Lipworth BJ The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPDChest2012 1418186

    Not in our library10.1378/chest.11-0038

  105. 105.

    Karner C Cates CJ The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease (Review)Cochrane Database Syst Rev2011 9CD009039

    Not in our library10.1002/14651858.cd009039.pub2

  106. 106.

    Hughes AD Jones LH Dual-pharmacology muscarinic antagonist and β2 agonist molecules for the treatment of chronic obstructive pulmonary diseaseFuture Med Chem2011 315851605

    Not in our library10.4155/fmc.11.106

  107. 107.

    Steinfeld T Hughes AD Klein U Smith JAM Mammen M THRX-198321 is a bifunctional muscarinic receptor antagonist and β2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent mannerMol Pharmacol2011 79389399

    Not in our library10.1124/mol.110.069120

  108. 108.
    Review: Rho kinase as a therapeutic target in the treatment of asthma and chronic obstructive pulmonary disease · 2007
    Not checked
  109. 109.

    IMS Health, LifeLink SolutionsIMS data 5/2011-4/20122012

    Not in our library

  110. 110.

    Vogelmeier C Hederer B Glaab T Schmidt H Rutten-van Mölken MPMH Beeh KM Rabe KF Fabbri LM for the POET-COPD InvestigatorsTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011 36410931103

    Not in our library10.1056/nejmoa1008378

  111. 111.

    Casaburi R Kukafka D Cooper CB Witek TJ Jr Kesten S Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPDChest2005 127809817

    Not in our library10.1378/chest.127.3.809

  112. 112.

    Maltais F Hamilton A Marciniuk D Hernandez P Sciurba FC Richter K Kesten S O'Donnell D Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPDChest2005 12811681178

    Not in our library10.1378/chest.128.3.1168

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.